Pasithea Therapeutics (KTTA) Short Interest Ratio & Short Volume

Short interest is the volume of Pasithea Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 416,900 shares of KTTA short. 19.04% of Pasithea Therapeutics' shares are currently sold short. Learn More on Pasithea Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.04% of Pasithea Therapeutics' floating shares are currently sold short.

Pasithea Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 416,900 shares, an increase of 2,795.1% from the previous total of 14,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Pasithea Therapeutics currently has issued a total of 2,705,000 shares. Some of Pasithea Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Pasithea Therapeutics currently has a public float of 2,190,000 shares.

19.04% of Pasithea Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Pasithea Therapeutics: Sol-Gel Technologies Ltd. (0.50%), Equillium, Inc. (1.10%), Unity Biotechnology, Inc. (4.83%), Cingulate Inc. (4.50%), Edesa Biotech, Inc. (0.90%), Natural Alternatives International, Inc. (0.09%), Lipocine Inc. (1.39%), Leap Therapeutics, Inc. (11.30%), Bullfrog AI Holdings, Inc. (7.34%), BioVie Inc. (6.44%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks.

Short selling KTTA is an investing strategy that aims to generate trading profit from Pasithea Therapeutics as its price is falling. KTTA shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Pasithea Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KTTA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KTTA, twice per month. The most recent reporting period available is April, 15 2025.